Multidrug resistance protein 2 genetic polymorphism and colorectal cancer recurrence in patients receiving adjuvant FOLFOX-4 chemotherapy

Molecular Medicine Reports

Volumn 7, Issue 2, 2013, Pages 613-617

  Mirakhorli, Mojgan ^a   Rahman, Sabariah Abdul ^a,b   Abdullah, Syahrilnizam ^a   Vakili, Masoud ^c   Rozafzon, Reza ^d   Khoshzaban, Ahad ^c,d  

^a UNIVERSITY PUTRA MALAYSIA   (Malaysia)

^b Universiti of Teknologi MARA   (Malaysia)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

ABCC2 MRP1; Colorectal cancer; G1249A; Oxaliplatin; Recurrence; Survival

Indexed keywords

FLUOROURACIL; FOLINIC ACID; MULTIDRUG RESISTANCE PROTEIN 2; OXALIPLATIN;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CANCER TISSUE; CASE CONTROL STUDY; CLINICAL ARTICLE; COLORECTAL CANCER; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HUMAN; HUMAN TISSUE; MALE; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; POSTOPERATIVE CARE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; WILD TYPE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; LEUCOVORIN; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RECURRENCE; RISK FACTORS; SURVIVAL RATE; YOUNG ADULT;

EID: 84873809577     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2012.1226     Document Type: Article

References (22)

1. Kuebler JP, Wieand HS, O'Connell MJ, et al: Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 25: 2198-2204, 2007.
2. Chen LT and Whang-Peng J: Current status of clinical studies for colorectal cancer in Taiwan. Clin Colorectal Cancer 4: 196-203, 2004.
3. de Gramont AD, Tournigand C, André T, Larsen AK and Louvet C: Adjuvant therapy for stage II and III colorectal cancer. Semin Oncol 34 (Suppl 1): S37-S40, 2007.
4. Schippinger W, Samonigg H, Schaberl-Moser R, et al: A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer. Br J Cancer 97: 1021-1027, 2007.
5. Gonzalez-Haba E, García MI, Cortejoso L, et al: ABCB1 gene polymorphisms are associated with adverse reactions in fluoropyrimidine-treated colorectal cancer patients. Pharmacogenomics11: 1715-1723, 2010.
6. Casado E, De Castro J, Belda-Iniesta C, et al: Molecular markers in colorectal cancer: genetic bases for a customised treatment. Clin Transl Oncol 9: 549-554, 2007.
7. Perez RP, Hamilton TC and Ozols RF: Resistance to alkylating agents and cisplatin: insights from ovarian carcinoma model systems. Pharmacol Ther 48: 19-27, 1990.
8. El-akawi Z, Abu-hadid M, Perez R, et al: Altered glutathione metabolism in oxaliplatin resistant ovarian carcinoma cells. Cancer Lett 105: 5-14, 1996.
9. Theile D, Grebhardt S, Haefeli WE and Weiss J: Involvement of drug transporters in the synergistic action of FOLFOX combination chemotherapy. Biochem Pharmacol 78: 1366-1373, 2009.
10. Ballatori N, Hammond CL, Cunningham JB, Krance SM and Marchan R: Molecular mechanisms of reduced glutathione transport: role of the MRP/CFTR/ABCC and OATP/SLC21A families of membrane proteins. Toxicol Appl Pharmacol 204: 238-255, 2005.
11. Sun N, Sun X, Chen B, et al: MRP2 and GSTP1 polymorphisms and chemotherapy response in advanced non-small cell lung cancer. Cancer Chemother Pharmacol 65: 437-446, 2010.
12. Nies AT and Keppler D: The apical conjugate efflux pump ABCC2 (MRP2). Pflugers Arch 453: 643-659, 2007.
13. Meyer zu Schwabedissen HE, Jedlitschky G, Gratz M, et al: Variable expression of MRP2 (ABCC2) in human placenta: influence of gestational age and cellular differentiation. Drug Metab Dispos 33: 896-904, 2005.
14. Kroetz DL, Liu W, Nguyen TD, et al: 1249G>A polymorphism of ABCC2 (MRP2) is associated with altered gene expression in human liver. J Clin Oncol 24 (Suppl): 13072, 2006.
15. Toh S, Wada M, Uchiumi T, et al: Genomic structure of the canalicular multispecific organic anion-transporter gene (MRP2/cMOAT) and mutations in the ATP-binding-cassette region in Dubin-Johnson syndrome. Am J Hum Genet 64: 739-746, 1999.
16. Choi JH, Ahn BM, Yi J, et al: MRP2 haplotypes confer differential susceptibility to toxic liver injury. Pharmacogenet Genomics 17: 403-415, 2007.
17. Naesens M, Kuypers DR, Verbeke K and Vanrenterghem Y: Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients. Transplantation 82: 1074-1084, 2006.
18. Liedert B, Materna V, Schadendorf D, Thomale J and Lage H: Overexpression of cMOAT (MRP2/ABCC2) is associated with decreased formation of platinum-DNA adducts and decreased G2-arrest in melanoma cells resistant to cisplatin. J Invest Dermatol 121: 172-176, 2003.
19. Shen DW, Goldenberg S, Pastan I and Gottesman MM: Decreased accumulation of [14C]carboplatin in human cisplatin-resistant cells results from reduced energy-dependent uptake. JCell Physiol 183: 108-116, 2000.
20. Petrova DT, Nedeva P, Maslyankov S, et al: No association between MDR1 (ABCB1) 2677G>T and 3435C>T polymorphism and sporadic colorectal cancer among Bulgarian patients. J Cancer Res Clin Oncol 134: 317-322, 2008.
21. Nishioka C, Sakaeda T, Nakamura T, et al: MDR1, MRP1 and MRP2 genotypes and invitro chemosensitivity in Japanese patients with colorectal adenocarcinomas. Kobe J Med Sci 50: 181-188, 2004.
22. Xingsheng Y, Sekine M, Kurata H, et al: Single nucleotide polymorphisms in MRP2 gene and their significance on chemosensitivity of advanced ovarian cancer. J Pract Obstet Gynecol20: 153-155, 2004.